Rhinil Tablet: Each film coated tablet contains Cetirizine Dihydrochloride INN 10 mg.
Rhinil Liquid: Each 5 ml of liquid contains Cetirizine Dihydrochloride INN 5 mg.
Cetirizine, a piperazine derivative and carboxylated metabolite of hydroxyzine, is a potent antihistamine with distinguishing features like: (1) Exquisite anti-H1 specificity: Cetirizine appears unique in being devoid of action on receptors other than the H1-receptor, (2) Potency: at unit dose Cetirizine is the most potent antihistamine in the skin and lungs & (3) Absence of metabolism. Therefore, Cetirizine is the choice of H1 antagonist for the management of the immediate allergic reactions. Cetirizine, a new second-generation H1-antagonist, is the only antihistamine that possesses activity against both the histamine mediated 'early' phase of the allergic reaction and the 'late' phase response of immediate hypersensitivity characterize by migration of inflammatory cells to the site of the reaction. It is an effective and well-tolerated treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria. The nonsedating antihistamine cetirizine is also effective on the treatment of allergen-induced asthma. It has no significant anticholinergic & antiserotonic effects.
Cetirizine is indicated for the symptomatic treatment of allergic rhinitis and urticaria.
Rhinil Tablet:
Rhinil Liquid:
Rhinil is contraindicated in patients who have shown hypersensitivity or idiosyncrasy to it or to its parent compound, Hydroxyzine.
Rhinil is well tolerated and associated with fewer adverse effects compared with first generation antihistamines. Side effects include headache, dry mouth, dizziness, agitation and gastrointestinal upset. Rhinil does not produce anticholinergic effects.
Pregnancy: Rituximab should not be administered to pregnant women unless the possible benefit outweighs the potential risk.
Nursing mothers: Rituximab should not be administered to nursing mothers.
Pediatric use: The safety and efficacy of Rituximab in children and adolescents (<18 years) have not been established.
Geriatric Use: No dose adjustment is required in patients aged ≥65 years of age.
Hepatic and Renal Insufficiency: The safety and efficacy of renal and hepatic impairment in Rituximab patients has not been established.
Patients are advised not to exceed the recommended dose if driving car or operating machinery. Caution should be taken with concommitant use of sedatives and some dose reduction may be required if renal fuction is impaired.
Store below 30 C, Keep in a dry place & protect from light. Keep out of the reach of children.